Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Chloe Yang, MD BS, Haiyan Jiang, PhD, Esther Masih-Khan, PhD, Christine I Chen, MD FRCP(C), Anca Prica, MD FRCP(C), Donna Reece, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 3462.

https://doi.org/10.1182/blood.V130.Suppl_1.3462.3462

Published: 2017

Journal Articles

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Donna Reece, BA, MD, John Mikhaeil, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat, Christine I Chen, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Anca Prica, MD FRCP(C), Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 2010.

https://doi.org/10.1182/blood.V130.Suppl_1.2010.2010

Published: 2017

Journal Articles

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Amanda Li, MD BSc, Eshetu G Atenafu, M.Sc., P.Stat, Rosanne St. Bernard, MD MSc, Esther Masih-Khan, PhD, Donna Reece, MD FRCP(C), Norman Anthony Franke, MD, Rodger Tiedemann, MBChB, PhD, Anca Prica, MD FRCP(C), Suzanne Trudel, MD FRCP(C), Vishal Kukreti, MD FRCP(C), Christine I Chen, MD FRCP(C)

Blood (2017) 130 (Supplement 1): 4537.

https://doi.org/10.1182/blood.V130.Suppl_1.4537.4537

Published: 2017

Journal Articles

Targeted-Capture Sequencing Approach to V(D)J Rearrangement, Immunoglobulin (Ig) Translocation and Mutation Detection in Multiple Myeloma (MM): Potential Applications in Minimal Residual Disease (MRD) Analysis and Comparison to Multiparameter Flow Cytometry (MFC) in the Myeloma Canada Research Network (MCRN) 001 Study with Intravenous Busulfan and Melphalan (BuMel) Conditioning Followed By Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2017) 130 (Supplement 1): 3057.

https://doi.org/10.1182/blood.V130.Suppl_1.3057.3057

Published: 2017

Journal Articles

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Abi Vijenthira, MD, Manjula Mangati, Michael Crump, MD, Vishal Kukreti, MD, John Kuruvilla, MD, Rodger Tiedemann, MD PhD, Christine Chen, MD, Anca Prica, MD

Blood (2016) 128 (22): 1795.

https://doi.org/10.1182/blood.V128.22.1795.1795

Published: 2016

Journal Articles

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Sara Farshchi Zarabi, MD, Esther Masih-Khan, PhD, Christine Chen, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 5821.

https://doi.org/10.1182/blood.V128.22.5821.5821

Published: 2016

Journal Articles

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Anca Prica, MD, Vinita Dhir, Nuchanan Areethamsirikul, MD, Christine Chen, MD, Donna Reece, MD, Suzanne Trudel, MD, Rodger Tiedemann, MBChB, PhD, Vishal Kukreti, MD

Blood (2016) 128 (22): 1184.

https://doi.org/10.1182/blood.V128.22.1184.1184

Published: 2016

Journal Articles

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Henry Siu Him Chan, MBChB, Madeline Phillips, Sophia Farooki, MD FRCPC, Giovanni Piza Rodriguez, MD, Esther Masih-Khan, PhD, Christine Chen, MD, Vishal Kukreti, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 3457.

https://doi.org/10.1182/blood.V128.22.3457.3457

Published: 2016

Journal Articles

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Julie Cote, MD, Madeline Phillips, Eshetu G Atenafu, MSc, PStat, Esther Masih-Khan, PhD, Donna Reece, MD, Christine Chen, MD, Anca Prica, MD, Rodger Tiedemann, MD PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2016) 128 (22): 2137.

https://doi.org/10.1182/blood.V128.22.2137.2137

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin W. Song, MD, Jean Roy, MD, Martha L Louzada, MD, Arleigh McCurdy, MD, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul, BSc

Blood (2016) 128 (22): 4632.

https://doi.org/10.1182/blood.V128.22.4632.4632

Published: 2016

Journal Articles

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite TMÂ chain (HLC) Normalization

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhDMSc, Darrell White, MD, Christopher P. Venner, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Prica Anca, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD, Harminder Paul

Blood (2015) 126 (23): 1982.

https://doi.org/10.1182/blood.V126.23.1982.1982

Published: 2015

Journal Articles

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Sara Farshchi-Zarabi, MD, Gurdeep Parmar, MD, Esther Masih-Khan, PhD, Sophia Farooki, MD FRCPC, Christine Chen, MD FRCPC, Vishal Kukreti, MD FRCPC, Anca Prica, MD FRCPC, Rodger Tiedemann, MBChB, FRCPC, PhD, Suzanne Trudel, MD, Donna Reece

Blood (2015) 126 (23): 3176.

https://doi.org/10.1182/blood.V126.23.3176.3176

Published: 2015

Journal Articles

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Majed Alahmadi, MBBS, FRCPC, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Limore Arones, Christine Chen, MD, Vishal Kukreti, MD, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Anca Prica, MD, Donna Reece

Blood (2015) 126 (23): 1842.

https://doi.org/10.1182/blood.V126.23.1842.1842

Published: 2015

Journal Articles

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Bethany E Monteith, MD, Esther Masih-Khan, PhD, Eshetu G Atenafu, M.Sc., P.Stat., Christine Chen, MD, Anca Prica, MD, Donna Reece, Rodger Tiedemann, MBChB, PhD, Suzanne Trudel, MD, Vishal Kukreti, MD

Blood (2015) 126 (23): 5361.

https://doi.org/10.1182/blood.V126.23.5361.5361

Published: 2015

Journal Articles

A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

Allison C. Rosenthal, DO, Amylou Constance Dueck, PhD, Katherine Gano, MS, Craig Nichols, Daniel Johnson, Angela Toro, NP, Sravan Nagi Reddy, James L Slack, MD, Jose F Leis, MD PhD, Donald W. Northfelt, MD, P. Leif Bergsagel, MD, Rodger Tiedemann, MBChB, PhD, Patrick B. Johnston, MD PhD, Thomas M Habermann, MD, Thomas E. Witzig, MD, Craig B. Reeder, MD

Blood (2014) 124 (21): 4410.

https://doi.org/10.1182/blood.V124.21.4410.4410

Published: 2014

Journal Articles

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

Michael Kennah, MD, Nastaran Noroozi, MD FRCPC, Esther Masih-Khan, PhD, Tony Panzarella, M.Sc., P.Stat., Donna E Reece, MD FRCPC, Suzanne Trudel, MD, Vishal Kukreti, MD FRCPC, Rodger Tiedemann, MBChB, PhD, Christine I. Chen, MD MD FRCPC

Blood (2014) 124 (21): 2019.

https://doi.org/10.1182/blood.V124.21.2019.2019

Published: 2014

Journal Articles

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity

Donna Reece, MD, Giovanni Piza Rodriguez, MD, Mariela Pantoja, PhD MSc, Christopher P. Venner, MD, Darrell White, MD, Julie Stakiw, MD, Michael Sebag, MD PhD, Terrance Comeau, MD, Kevin Song, MD, Jean Roy, MD, Leonard Minuk, MD, Jason Tay, MD MSc, Vishal Kukreti, MD, Suzanne Trudel, MD, Anca Prica, MD, Rodger Tiedemann, MBChB, PhD, Christine Chen, MD

Blood (2014) 124 (21): 3990.

https://doi.org/10.1182/blood.V124.21.3990.3990

Published: 2014

Journal Articles

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Yuan Xiao Zhu, Rodger Tiedemann, Chang-Xin Shi, Holly Yin, Jessica E. Schmidt, Laura A. Bruins, Jonathan J. Keats, Esteban Braggio, Chris Sereduk, Spyro Mousses, A. Keith Stewart

Blood (2011) 117 (14): 3847–3857.

https://doi.org/10.1182/blood-2010-08-304022

Published: 2011

Includes: Supplemental data

Journal Articles

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Craig B. Reeder, Donna E. Reece, Vishal Kukreti, Christine Chen, Suzanne Trudel, Kristina Laumann, Joseph Hentz, Nicholas A. Pirooz, Jesus G. Piza, Rodger Tiedemann, Joseph R. Mikhael, Peter L. Bergsagel, Jose F. Leis, Rafael Fonseca, Alexander K. Stewart

Blood (2010) 115 (16): 3416–3417.

https://doi.org/10.1182/blood-2010-02-271676

Published: 2010

Journal Articles

Cyproheptadine displays preclinical activity in myeloma and leukemia

Blood (2008) 112 (3): 760–769.

https://doi.org/10.1182/blood-2008-02-142687

Published: 2008

Includes: Supplemental data

NARROW

Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience

Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review

Toxicity and Outcomes of Autologous Stem Cell Transplant in Multiple Myeloma Patients with Renal Insufficiency: An Institutional Comparison between Two Eras

Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab NaïVe Patients?

Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy

Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model

Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant

Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting

Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?

Addition of Cyclophosphamide, on Demand, to Lenalidomide and Corticosteroids in Patients with Relapsed/Refractory Multiple Myeloma, a Retrospective Review of a Single Centre Experience

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma

Patient, Disease and Treatment Characteristics of Long-Term Survivors of Multiple Myeloma

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5

Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Cyproheptadine displays preclinical activity in myeloma and leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only